Literature DB >> 22282644

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Robert J Fox1, Richard A Rudick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22282644     DOI： 10.1212/WNL.0b013e318245d2d0

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  14 in total

1.  Reassessing the risk of natalizumab-associated PML.

Authors:  Joseph R Berger; Robert J Fox
Journal:  J Neurovirol       Date:  2016-02-03       Impact factor: 2.643

2.  [Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].

Authors:  J-P Stellmann; K H Stürner; F Ufer; S Havemeister; J Pöttgen; F Ayuk Ayuketang; N Kröger; M A Friese; C Heesen
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

3.  Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.

Authors:  Douglas R Jeffery
Journal:  Ther Adv Chronic Dis       Date:  2013-01       Impact factor: 5.091

4.  Medical decisions are not just about the facts: What a life-threatening virus can teach us about empathy, psychology, and the practice of neurology.

Authors:  Norman J Kachuck
Journal:  Neurol Clin Pract       Date:  2012-06

5.  New disease-modifying therapies and new challenges for MS.

Authors:  Vijayshree Yadav; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

6.  Progressive Multifocal Leukoencephalopathy Risk Perception in Patients Considering Natalizumab for Multiple Sclerosis.

Authors:  Regina Berkovich; Jonathan Eskenazi; Aida Yakupova; Evan Lawrence Riddle
Journal:  Int J MS Care       Date:  2021-04-08

7.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 8.  Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.

Authors:  Daniel Ontaneda; Daniela Di Capua
Journal:  Ther Adv Drug Saf       Date:  2012-12

Review 9.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

10.  Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.

Authors:  Paul Wicks; David Brandes; Jinhee Park; Dimitri Liakhovitski; Tatiana Koudinova; Rahul Sasane
Journal:  Interact J Med Res       Date:  2015-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.